These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21998474)

  • 1. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.
    Schepens B; Ibañez LI; De Baets S; Hultberg A; Bogaert P; De Bleser P; Vervalle F; Verrips T; Melero J; Vandevelde W; Vanlandschoot P; Saelens X
    J Infect Dis; 2011 Dec; 204(11):1692-701. PubMed ID: 21998474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice.
    Haynes LM; Caidi H; Radu GU; Miao C; Harcourt JL; Tripp RA; Anderson LJ
    J Infect Dis; 2009 Aug; 200(3):439-47. PubMed ID: 19545210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
    Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.
    Voges B; Vallbracht S; Zimmer G; Bossow S; Neubert WJ; Richter K; Hobeika E; Herrler G; Ehl S
    Cell Immunol; 2007 Jun; 247(2):85-94. PubMed ID: 17904538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
    Kim S; Jang JE; Yu JR; Chang J
    Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
    Lagos R; DeVincenzo JP; Muñoz A; Hultquist M; Suzich J; Connor EM; Losonsky GA
    Pediatr Infect Dis J; 2009 Sep; 28(9):835-7. PubMed ID: 19636278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.
    Huang K; Incognito L; Cheng X; Ulbrandt ND; Wu H
    J Virol; 2010 Aug; 84(16):8132-40. PubMed ID: 20519399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.
    Detalle L; Stohr T; Palomo C; Piedra PA; Gilbert BE; Mas V; Millar A; Power UF; Stortelers C; Allosery K; Melero JA; Depla E
    Antimicrob Agents Chemother; 2016 Jan; 60(1):6-13. PubMed ID: 26438495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive IgA monoclonal antibody is no more effective than IgG at protecting mice from mucosal challenge with respiratory syncytial virus.
    Fisher RG; Crowe JE; Johnson TR; Tang YW; Graham BS
    J Infect Dis; 1999 Oct; 180(4):1324-7. PubMed ID: 10479165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a synthetic peptide as a replacement for the recombinant fusion protein of respiratory syncytial virus in a potency ELISA.
    McGivney JB; Bishop E; Miller K; Casas-Finet J; Yang H; Wei Z; Strouse R; Schenerman M
    J Pharm Biomed Anal; 2011 Feb; 54(3):572-6. PubMed ID: 20943340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New strategies for control of respiratory syncytial virus infection.
    Nokes JD; Cane PA
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.
    Skaricic D; Traube C; De B; Joh J; Boyer J; Crystal RG; Worgall S
    Virology; 2008 Aug; 378(1):79-85. PubMed ID: 18556039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H; Pfarr DS; Johnson S; Brewah YA; Woods RM; Patel NK; White WI; Young JF; Kiener PA
    J Mol Biol; 2007 May; 368(3):652-65. PubMed ID: 17362988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Progress in the F Gene and Protein of the Respiratory Syncytial Virus].
    Zhang F; Xie Z
    Bing Du Xue Bao; 2015 Mar; 31(2):201-6. PubMed ID: 26164949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
    J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.